Unknown

Dataset Information

0

Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery.


ABSTRACT: New generation vaccines are in demand to include only the key antigens sufficient to confer protective immunity among the plethora of pathogen molecules. In the last decade, large-scale genomics-based technologies have emerged. Among them, the Reverse Vaccinology approach was successfully applied to the development of an innovative vaccine against Neisseria meningitidis serogroup B, now available on the market with the commercial name BEXSERO® (Novartis Vaccines). The limiting step of such approaches is the number of antigens to be tested in in vivo models. Several laboratories have been trying to refine the original approach in order to get to the identification of the relevant antigens straight from the genome. Here we report a new bioinformatics tool that moves a first step in this direction. The tool has been developed by identifying structural/functional features recurring in known bacterial protective antigens, the so called "Protectome space," and using such "protective signatures" for protective antigen discovery. In particular, we applied this new approach to Staphylococcus aureus and Group B Streptococcus and we show that not only already known protective antigens were re-discovered, but also two new protective antigens were identified.

SUBMITTER: Altindis E 

PROVIDER: S-EPMC4350036 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Protectome analysis: a new selective bioinformatics tool for bacterial vaccine candidate discovery.

Altindis Emrah E   Cozzi Roberta R   Di Palo Benedetta B   Necchi Francesca F   Mishra Ravi P RP   Fontana Maria Rita MR   Soriani Marco M   Bagnoli Fabio F   Maione Domenico D   Grandi Guido G   Liberatori Sabrina S  

Molecular & cellular proteomics : MCP 20141103 2


New generation vaccines are in demand to include only the key antigens sufficient to confer protective immunity among the plethora of pathogen molecules. In the last decade, large-scale genomics-based technologies have emerged. Among them, the Reverse Vaccinology approach was successfully applied to the development of an innovative vaccine against Neisseria meningitidis serogroup B, now available on the market with the commercial name BEXSERO® (Novartis Vaccines). The limiting step of such appro  ...[more]

Similar Datasets

| S-EPMC5737611 | biostudies-literature
| S-EPMC7902242 | biostudies-literature
| S-EPMC2702496 | biostudies-literature
| S-EPMC6350973 | biostudies-literature
| S-EPMC6161673 | biostudies-literature
| S-EPMC9320593 | biostudies-literature
| S-EPMC6020400 | biostudies-literature
| S-EPMC7734488 | biostudies-literature
| S-EPMC3059205 | biostudies-literature
| S-EPMC6478441 | biostudies-literature